Its interesting. Whether I ("we") believe him or not this certainly may have a mid term (its already had a short term) negative impact on the stock. Unfortunately for longs this negative news, whether accurate or not, will not be repudiated accept through continued use of the drug. I would tend to think that it can't be nearly as bad as described or we would have seen worse adverse effects during the trials. However, it doesn't matter if the author is wrong, the short term damage has been done and it might not be correctable other than through the continued use of the drug. Oy Vey biotech investing is never easy.
I would love for some of the former board experts (BIOMAVIN or DonShimmonda to chime in
Market Data 
Markets 
AI
